The Methylenetetrahydrofolate Reductase (MTHFR) C677T Gene Polymorphism is Associated with Breast Cancer Subtype Susceptibility in Southwestern China

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2021 Jul 9

PMID 34242313

Citations 4

Authors

Zhen Li

Ji Zhang

Wei Zou

Qi Xu

Siyuan Li

Jie Wu

Li Zhu

Yunjiao Zhang

Lei Xu

Ying Zhang

Qingsong Luo

Jianyun Nie

Xingxu Li

Tianning Zou

Ceshi Chen

Affiliations

Soon will be listed here.

Abstract

Methylenetetrahydrofolate reductase (MTHFR), a folate-dependent enzyme, is reportedly involved in several cancer types. The MTHFR C677T polymorphism influences many biological processes, including tumorigenesis. However, the association between the MTHFR C677T polymorphism and breast cancer (BC) subtypes is not fully understood. In this study, the MTHFR C677T polymorphism was genotyped in 490 individuals with or without BC from southwestern China. Analysis of the association between the MTHFR C677T polymorphism and BC revealed that there was a significant association between the MTHFR C677T polymorphism and triple-negative breast cancer (TNBC) (OR = 2.83, 95% CI: 1.12-9.51, P = 0.0401). Furthermore, the MTHFR C677T polymorphism can also serve as a protective factor in luminal A breast cancer (OR = 0.57, 95% CI: 0.34-0.94, P = 0.0258). Evaluation of the association between the MTHFR C677T polymorphism and clinical characteristics indicated that people who suffered from hypertension had an increased risk for BC (OR = 2.27; 95% CI: 1.08-4.6; P = 0.0264), especially TNBC (OR = 215.38; 95% CI: 2.45-84430.3; P = 0.0317). Our results suggest that the MTHFR C677T polymorphism is significantly associated with susceptibility to luminal B breast cancer and TNBC.

Citing Articles

Investigating the Matrix of Factor V Leiden (G1691A), Factor II Prothrombin (G2021A), MTHFR C677T and A1298G Polymorphisms in Greek Population: A Preliminary Study.

Spanoudaki M, Itziou A, Cheimaras A, Tsiripidis O, Risvas G, Tsitlakidou N Med Sci (Basel). 2024; 12(4).

PMID: 39584911 PMC: 11587029. DOI: 10.3390/medsci12040061.

Detection of Methylene Tetrahydrofolate Reductase (MTHFR C677T) Mutation among Acute Lymphoblastic Leukemia in Sudanese Patients.

Mohieldeen W, Ahmed A, Elmosaad Y, Suliman R, Alfahed A, Hjazi A Rep Biochem Mol Biol. 2024; 12(3):458-464.

PMID: 38618256 PMC: 11015921. DOI: 10.61186/rbmb.12.3.458.

The gene polymorphisms of eNOS and MTHFR modulates the development of preeclampsia in Han population.

Rao J, Chen Y, Chen X, Wu R, Luo S, Lin Q Heliyon. 2023; 9(12):e22223.

PMID: 38076047 PMC: 10709003. DOI: 10.1016/j.heliyon.2023.e22223.

C677T Gene Polymorphism of MTHFR Is a Risk Factor for Impaired Renal Function in Pregnant Women With Preeclampsia in the Chinese Han Population.

Yun L, Ge M, Xu R, Zheng F, Zhao X, Li X Front Cardiovasc Med. 2022; 9:902346.

PMID: 35711354 PMC: 9196626. DOI: 10.3389/fcvm.2022.902346.

References

McNulty H, Strain J, Hughes C, Ward M . Riboflavin, MTHFR genotype and blood pressure: A personalized approach to prevention and treatment of hypertension. Mol Aspects Med. 2016; 53:2-9. DOI: 10.1016/j.mam.2016.10.002. View

Kawakita D, Lee Y, Gren L, Buys S, La Vecchia C, Hashibe M . The impact of folate intake on the risk of head and neck cancer in the prostate, lung, colorectal, and ovarian cancer screening trial (PLCO) cohort. Br J Cancer. 2017; 118(2):299-306. PMC: 5785740. DOI: 10.1038/bjc.2017.383. View

Ritchie C, Kvale E, Fisch M . Multimorbidity: an issue of growing importance for oncologists. J Oncol Pract. 2012; 7(6):371-4. PMC: 3219463. DOI: 10.1200/JOP.2011.000460. View

Castiglia P, Sanna V, Azara A, De Miglio M, Murgia L, Pira G . Methylenetetrahydrofolate reductase (MTHFR) C677T and A1298C polymorphisms in breast cancer: a Sardinian preliminary case-control study. Int J Med Sci. 2019; 16(8):1089-1095. PMC: 6743281. DOI: 10.7150/ijms.32162. View

Christensen B, Kelsey K, Zheng S, Houseman E, Marsit C, Wrensch M . Breast cancer DNA methylation profiles are associated with tumor size and alcohol and folate intake. PLoS Genet. 2010; 6(7):e1001043. PMC: 2912395. DOI: 10.1371/journal.pgen.1001043. View

Cuorvo L, Verderio P, Ciniselli C, Girlando S, Decarli N, Leonardi E . PI3KCA mutation status is of limited prognostic relevance in ER-positive breast cancer patients treated with hormone therapy. Virchows Arch. 2013; 464(1):85-93. DOI: 10.1007/s00428-013-1500-7. View

Chmurzynska A, Malinowska A, Twardowska-Rajewska J, Gawecki J . Elderly women: homocysteine reduction by short-term folic acid supplementation resulting in increased glucose concentrations and affecting lipid metabolism (C677T MTHFR polymorphism). Nutrition. 2013; 29(6):841-4. DOI: 10.1016/j.nut.2012.09.015. View

Barone B, Yeh H, Snyder C, Peairs K, Stein K, Derr R . Long-term all-cause mortality in cancer patients with preexisting diabetes mellitus: a systematic review and meta-analysis. JAMA. 2008; 300(23):2754-64. PMC: 3093051. DOI: 10.1001/jama.2008.824. View

Erickson J . Folic acid and prevention of spina bifida and anencephaly. 10 years after the U.S. Public Health Service recommendation. MMWR Recomm Rep. 2002; 51(RR-13):1-3. View

10.

Schoemaker M, Nichols H, Wright L, Brook M, Jones M, OBrien K . Adult weight change and premenopausal breast cancer risk: A prospective pooled analysis of data from 628,463 women. Int J Cancer. 2020; 147(5):1306-1314. PMC: 7365745. DOI: 10.1002/ijc.32892. View

11.

Chen S, Rong L, Lei Q, Cao P, Qin S, Zheng D . A surface charge-switchable and folate modified system for co-delivery of proapoptosis peptide and p53 plasmid in cancer therapy. Biomaterials. 2015; 77:149-63. DOI: 10.1016/j.biomaterials.2015.11.013. View

12.

Meneses-Sanchez P, Garcia-Hernandez S, Porchia L, Perez-Fuentes R, Torres-Rasgado E, Del Angel Soto A . C677T and A1298C methylenetetrahydrofolate reductase polymorphisms and breast cancer susceptibility among Latinos: a meta-analysis. Breast Cancer. 2019; 26(5):602-611. DOI: 10.1007/s12282-019-00961-8. View

13.

Calip G, Yu O, Hoskins K, Boudreau D . Associations between diabetes medication use and risk of second breast cancer events and mortality. Cancer Causes Control. 2015; 26(8):1065-77. PMC: 4501774. DOI: 10.1007/s10552-015-0599-z. View

14.

Howlader N, Altekruse S, Li C, Chen V, Clarke C, Ries L . US incidence of breast cancer subtypes defined by joint hormone receptor and HER2 status. J Natl Cancer Inst. 2014; 106(5). PMC: 4580552. DOI: 10.1093/jnci/dju055. View

15.

Denkert C, Liedtke C, Tutt A, von Minckwitz G . Molecular alterations in triple-negative breast cancer-the road to new treatment strategies. Lancet. 2016; 389(10087):2430-2442. DOI: 10.1016/S0140-6736(16)32454-0. View

16.

Lamprecht S, Lipkin M . Chemoprevention of colon cancer by calcium, vitamin D and folate: molecular mechanisms. Nat Rev Cancer. 2003; 3(8):601-14. DOI: 10.1038/nrc1144. View

17.

Ferrari A, Torrezan G, Carraro D, Junior S . Association of Folate and Vitamins Involved in the 1-Carbon Cycle with Polymorphisms in the Methylenetetrahydrofolate Reductase Gene (MTHFR) and Global DNA Methylation in Patients with Colorectal Cancer. Nutrients. 2019; 11(6). PMC: 6627304. DOI: 10.3390/nu11061368. View

18.

Nam S, Park S, Park H, Kim S, Kim J, Kim S . Association Between Insulin Resistance and Luminal B Subtype Breast Cancer in Postmenopausal Women. Medicine (Baltimore). 2016; 95(9):e2825. PMC: 4782848. DOI: 10.1097/MD.0000000000002825. View

19.

De Ocampo M, Araneta M, Macera C, Alcaraz J, Moore T, Chambers C . Folic acid supplement use and the risk of gestational hypertension and preeclampsia. Women Birth. 2017; 31(2):e77-e83. DOI: 10.1016/j.wombi.2017.08.128. View

20.

DeSantis C, Ma J, Gaudet M, Newman L, Miller K, Sauer A . Breast cancer statistics, 2019. CA Cancer J Clin. 2019; 69(6):438-451. DOI: 10.3322/caac.21583. View